Bioxyne Limited (ASX:BXN)

Bioxyne Statistics

Total Valuation

Bioxyne has a market cap or net worth of AUD 100.80 million. The enterprise value is 94.36 million.

Market Cap	100.80M
Enterprise Value	94.36M

Important Dates

The next estimated earnings date is Wednesday, February 25, 2026.

Earnings Date	Feb 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Bioxyne has 2.24 billion shares outstanding. The number of shares has increased by 11.36% in one year.

Current Share Class	2.24B
Shares Outstanding	2.24B
Shares Change (YoY)	+11.36%
Shares Change (QoQ)	+5.06%
Owned by Insiders (%)	52.87%
Owned by Institutions (%)	n/a
Float	692.16M

Valuation Ratios

The trailing PE ratio is 19.57.

PE Ratio	19.57
Forward PE	n/a
PS Ratio	3.44
PB Ratio	8.33
P/TBV Ratio	8.12
P/FCF Ratio	23.96
P/OCF Ratio	16.06
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.39, with an EV/FCF ratio of 22.42.

EV / Earnings	19.25
EV / Sales	3.22
EV / EBITDA	16.39
EV / EBIT	18.50
EV / FCF	22.42

Financial Position

The company has a current ratio of 2.46, with a Debt / Equity ratio of 0.13.

Current Ratio	2.46
Quick Ratio	1.59
Debt / Equity	0.13
Debt / EBITDA	0.27
Debt / FCF	0.36
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 63.65% and return on invested capital (ROIC) is 85.44%.

Return on Equity (ROE)	63.65%
Return on Assets (ROA)	24.26%
Return on Invested Capital (ROIC)	85.44%
Return on Capital Employed (ROCE)	38.70%
Weighted Average Cost of Capital (WACC)	7.12%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	2.23
Inventory Turnover	6.30

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +9.52% in the last 52 weeks. The beta is 0.54, so Bioxyne's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	+9.52%
50-Day Moving Average	0.04
200-Day Moving Average	0.04
Relative Strength Index (RSI)	58.34
Average Volume (20 Days)	2,967,031

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bioxyne had revenue of AUD 29.28 million and earned 4.90 million in profits. Earnings per share was 0.00.

Revenue	29.28M
Gross Profit	11.18M
Operating Income	5.10M
Pretax Income	4.90M
Net Income	4.90M
EBITDA	5.40M
EBIT	5.10M
Earnings Per Share (EPS)	0.00

Balance Sheet

The company has 7.67 million in cash and 1.53 million in debt, with a net cash position of 6.13 million or 0.00 per share.

Cash & Cash Equivalents	7.67M
Total Debt	1.53M
Net Cash	6.13M
Net Cash Per Share	0.00
Equity (Book Value)	12.10M
Book Value Per Share	0.01
Working Capital	9.34M

Cash Flow

In the last 12 months, operating cash flow was 6.28 million and capital expenditures -2.07 million, giving a free cash flow of 4.21 million.

Operating Cash Flow	6.28M
Capital Expenditures	-2.07M
Free Cash Flow	4.21M
FCF Per Share	0.00

Margins

Gross margin is 38.17%, with operating and profit margins of 17.42% and 16.74%.

Gross Margin	38.17%
Operating Margin	17.42%
Pretax Margin	16.74%
Profit Margin	16.74%
EBITDA Margin	18.45%
EBIT Margin	17.42%
FCF Margin	14.37%

Dividends & Yields

Bioxyne does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.36%
Shareholder Yield	-11.36%
Earnings Yield	4.86%
FCF Yield	4.17%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Bioxyne has an Altman Z-Score of 5.69 and a Piotroski F-Score of 7.

Altman Z-Score	5.69
Piotroski F-Score	7